Kolexia
Berton Dominique Oncologie médicale
Berton Dominique
Oncologie médicale
Institut de cancérologie de l'Ouest
Saint-Herblain, France
188 Activités
1 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de l'ovaire Carcinome épithélial de l'ovaire Récidive tumorale locale Tumeurs du sein Carcinomes Tumeurs de l'endomètre Hypersensibilité Fatigue Métastase tumorale

Collaborateurs

Voir plus
Floquet Anne
Floquet Anne
Institut Bergonié, Bordeaux, France
Joly Florence
Joly Florence
Hôpital Côte de Nacre, Caen, France
Fabbro Michel
Fabbro Michel
Icm Montpellier, Montpellier, France
Alexandre Jerome
Alexandre Jerome
Cabinet libéral, Paris, France

Industries

Voir plus
AstraZeneca
7 collaboration(s)
Dernière en 2023
PUBLICLIN
6 collaboration(s)
Dernière en 2022
GSK
5 collaboration(s)
Dernière en 2023
Novartis
4 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer.
Gynecologic oncology   26 février 2024
ALEPRO: A Phase II, Open-label, Multicenter Study of Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer
Essai Clinique (Lilly)   09 février 2024
Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society   19 janvier 2024
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy: Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Essai Clinique (AstraZeneca)   15 janvier 2024
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society   21 décembre 2023
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.
JAMA network open   01 novembre 2023
815P Clinical outcome of metastatic endometrial carcinoma patients treated with chemotherapy: ENDOVIE, a GINECO national observational cohort study
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
755P Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H)
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
ONCOCOL01: Phase III Study Comparing Neoadjuvant Chemotherapy With Carboplatin and Paclitaxel Followed by Standard Therapy, With Standard Therapy Alone in Women With Cervical Cancer and Para Aortic Positive Lymph Node.
Essai Clinique (CHU Toulouse)   18 septembre 2023
MYCA: Phase Ib / II Trial Evaluating the Association Myocet ® - Carboplatine in Patients Having a Cancer of the Ovary in Relapse, Sensitive to the Platinum
Essai Clinique (ARCAGY/ GINECO GROUP)   05 septembre 2023